Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms

Study acronym: MPN-RC 127
StatusNot Yet Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This is a phase II, multicenter, open-label study evaluating the feasibility, safety, and efficacy of oral tetrahydrouridine-decitabine (THU-decitabine) in patients with advanced myeloproliferative neoplasms (MPN).
Trial Details
NCT Number NCT07872709
Lead Sponsor John Mascarenhas
Collaborators: Treebough Therapies, National Cancer Institute (NCI)
Conditions
(from sponsor)		 Myelofibrosis, MPN - Accelerated or Blast Phase, Chric Phase MPN
Related terms Blast Crisis, Primary Myelofibrosis
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov